相关实验视频
Updated: Jul 24, 2025

06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
23.5K
在用sacubitril/valsartan治疗期间,中区域前腺腺素的变化
Peder L Myhre1, Yuxi Liu2, Ian J Kulac3
1Division of Medicine, Akershus University Hospital and K.G. Jebsen Center for Cardiac Biomarkers, University of Oslo, Oslo, Norway.
European journal of heart failure
|July 4, 2023
概括
在心力衰竭患者中,萨库比特里尔/瓦尔萨坦 (Sac/Val) 治疗显著增加了中区域前腺腺素素 (MR-proADM) 水平. 然而,这些增加与心脏功能或患者健康状况的改善无关.
科学领域:
- 心血管医学 心血管医学
- 生物标志物 生物标志物
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿德雷诺美杜林是一种血管扩张性,对微循环和内皮平衡至关重要.
- 作为不利素基质,阿德伦米杜林可能会影响萨库比特里尔/瓦尔沙坦 (Sac/Val) 的治疗效果.
研究的目的:
- 为了研究心力衰竭患者在萨库比特里尔/瓦尔萨坦 (Sac/Val) 治疗后中区域前腺腺素 (MR-proADM) 水平的变化.
- 探索用Sac/Val.治疗心力衰竭患者MR-proADM变化与临床结果之间的相关性.
主要方法:
- 在接受Sac/Val或瓦尔萨坦治疗的心力衰竭患者中测量了MR-proADM水平,其中包括心力衰竭的减少喷射分数 (HFrEF) 和心力衰竭的保存喷射分数 (HFpEF).
- 在HFrEF队列中进行了心声回声和生活质量评估.
- 分析了MR-proADM的变化与Sac/Val剂量,NT-proBNP,Troponin T和尿循环GMP的关系.
主要成果:
- 在12周的Sac/Val治疗后,MR-proADM水平在HFrEF和HFpEF患者中显著增加 (49-60%).
- 在接受单独瓦尔萨坦治疗的患者中,没有观察到MR-proADM的显著变化 (2%的增加).
- 增加的MR-proADM与降低血压相关,但与其他生物标志物的相关性较弱,与心声学参数或健康状况改善无显著关联.
结论:
- 萨库比特里尔/瓦尔萨坦治疗导致MR-proADM的显著增加,与瓦尔萨坦单一治疗不同.
- 观察到的MR-proADM的增加与心脏结构,功能或患者报告的健康状况的改善无关.
- 需要进一步的研究,以阐明阿德伦美杜林及其在心力衰竭管理中的确切作用.
更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
Antihypertensive Drugs: Angiotensin II Receptor Blockers
786
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
786
Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Heart Failure V: Medical Management
15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
698
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
698
Hormonal Regulation
33.4K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.4K

